

Supplementary Online Content

Tay-Teo K, Ilbawi A, Hill SR. Comparison of sales income and research and development costs for FDA-approved cancer drugs sold by originator drug companies. *JAMA Netw Open*. 2019;2(1):e186875. doi:10.1001/jamanetworkopen.2018.6875

eTable. Reported and Derived (shaded) Sales Incomes in US Dollar, by Molecule

This supplementary material has been provided by the authors to give readers additional information about their work.

eTable. Reported and derived (shaded) sales incomes in US dollar, by molecule

Nr	Medicine name	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	
Medicines included																															
1	Abiraterone																								30.1	96.1	16.98	22.37	22.31	22.60	25.05
2	Acalabrutinib																														3.0
3	Aflibercept																									32.1	70.4	91.5	85.4	71.9	84.6
4	Alectinib																													18.4	36.7
5	Anastrozole								69.3	104.6	12.0	14.0	15.0	19.0	33.0	51.9	81.1	11.81	15.08	17.30	18.57	19.21	15.12	75.6	54.3	35.1	29.8	25.0	23.2	21.7	
6	Aprepitant																		13.0	20.1	25.9	31.3	37.8	41.9	48.9	50.7	55.3	53.5	54.9	55.6	
7	Atezolizumab																													15.9	49.4
8	Axitinib																								10.0	31.9	41.0	43.0	40.1	33.9	
9	Azacitidine																				20.6	38.7	53.4	70.5	82.3	82.6	69.0	67.5	67.4	66.0	
10	Belinostat																											5.0	10.1	13.4	12.4
11	Bendamustine																							9.1	40.1	43.9	40.0	34.9	33.9	41.4	64.2
12	Bevacizumab																55.5	13.37	23.62	34.21	48.07	57.18	61.94	59.59	61.45	75.01	70.05	69.48	68.86	67.89	
13	Bicalutamide								12.7	17.6	24.5	34.0	43.0	56.9	64.4	85.4	10.12	11.23	12.06	13.35	12.58	84.4	57.9	55.0	45.4	37.6	32.0	26.7	24.7	21.5	

Nr	Medicine name	1998	1999	1999	1999	1999	1999	1999	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017		
40	Fulvestrant														35.0	77.0	99.0	14.0	18.0	21.0	24.0	26.0	34.0	54.0	65.0	68.0	72.0	70.0	83.0	94.0		
41	Gefitinib														67.0	8.0	9.0	22.0	38.0	27.0	23.0	23.0	26.0	29.0	39.0	55.0	61.0	64.0	62.0	54.0	51.0	52.0
42	Gemcitabine							11.0	17.0	30.0	45.0	55.0	72.0	87.0	10.0	12.0	13.0	14.0	15.0	17.0	13.0	11.0	45.0	15.0	10.0							
43	Goserelin	8.1	1.4	1.0	2.5	3.6	4.8	52.0	57.0	62.0	68.0	73.0	72.0	79.0	86.0	91.0	10.0	10.0	11.0	11.0	10.0	11.0	11.0	10.0	99.0	92.0	81.0	81.0	73.0			
44	Granisetron												22.0	28.0	32.0	36.0	40.0	39.0	35.0	10.0												
45	Hpv Quadrivalent Vaccine																	23.0	14.0	14.0	11.0	98.0	12.0	16.0	18.0	17.0	19.0	21.0	23.0			
46	Ibritumomab Tiuxetan													13.0	19.0	18.0	19.0	16.0	13.0	11.0	15.0	29.0	27.0	30.0	29.0	24.0	17.0	10.0	11.0			
47	Ibrutinib																									13.0	74.0	14.0	30.0	44.0		
48	Idelalisib																															
49	Imatinib												15.0	61.0	11.0	16.0	21.0	25.0	30.0	36.0	39.0	42.0	46.0	46.0	46.0	47.0	46.0	33.0	19.0			
50	Ipilimumab												2.0	1.0	28.0	34.0	70.0	54.0	50.0	70.0	44.0	65.0	59.0	75.0	93.0	46.0	58.0	23.0	43.0			
51	Irinotecan						1.0	59.0	15.0	19.0	29.0	44.0	61.0	57.0	29.0	55.0	91.0	90.0	96.0	56.0	33.0	11.0	10.0	7.0	5.0	95.0	85.0	77.0	69.0	58.0		

